Displaying 1 - 12 of 26
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Metabolism, Alcohol & Toxicity
1

Bristol Myers Squibb: NASH: An evolution in treatment response tools - ILC 2021

View
Liver Tumours
5

Bristol-Myers Squibb: Evolving Treatment Landscape of HCC - Digital ILC 2020

View
Displaying 1 - 12 of 26